Metagenomi Therapeutics

MGXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$46.306 M

$1.23 -0.81%

Close of 7 Aug 2026

Revenue

$25.2M

#2938 by revenue

Earnings

-$87.9M

Loss-making

Shares outstanding

37,620,530

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#130Black Hawk AcquisitionBKHA$48.9M
#131ExozymesEXOZ$47.0M
#132Metagenomi TherapeuticsMGX$46.3M
#133TevogenTVGN$41.5M
#134ElutiaELUT$37.6M

Where these numbers come from

Share counts and financials for Metagenomi Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.